Ovation支架近端瘤颈封堵按适应证与超适应证使用的中期结果
多中心回顾性注册研究比较Ovation支架按原说明书瘤颈≥7 mm使用与超适应证用于瘤颈<7 mm的中期结局。89例腹主动脉瘤患者随访至少24个月,两组在Ia型内漏免除率、装置相关再干预免除率上无显著差异,且无动脉瘤相关死亡、破裂、支架移位或瘤颈扩大。
要点
- 瘤颈<7 mm超适应证使用Ovation支架的中期结局与≥7 mm者相似
- 3年无动脉瘤相关死亡、破裂、支架移位或瘤颈扩大
- Ia型内漏免除率和装置相关再干预免除率两组无显著差异
核心结论
- Ovation支架用于瘤颈长度<7 mm患者的中期结局与瘤颈≥7 mm患者相似。
- 中期数据表明Ovation系统治疗肾下腹主动脉瘤不受传统主动脉瘤颈长度测量限制,支持FDA近期对说明书的修改。
研究设计与样本
- 多中心回顾性注册研究(TriVascular Ovation Italian Study),纳入意大利13个中心使用Ovation支架行EVAR且CT随访至少24个月的患者89例。
- 患者平均年龄76.4±2.4岁,84例男性,平均随访32个月(范围24-50个月)。
- 按近端瘤颈长度分为IFU组(≥7 mm,n=57)和超适应证组(<7 mm,n=32)。
主要发现
- 3年时无动脉瘤相关死亡、破裂、支架移位或瘤颈扩大。
- Ia型内漏免除率IFU组98.2% vs 超适应证组96.8%(p=0.6;HR 0.55,95%CI 0.02-9.71)。
- 任何装置相关再干预免除率IFU组92.8% vs 超适应证组96.4%(p=0.4;HR 2.42,95%CI 0.34-12.99)。
- 封堵区直径平均变化IFU组-0.05±0.8 mm,超适应证组-0.1±0.5 mm。
临床怎么用
- 对于近端瘤颈<7 mm的肾下腹主动脉瘤患者,可考虑使用Ovation支架行EVAR,其中期结局与瘤颈≥7 mm者相似。
- 该中期数据支持Ovation系统不受传统瘤颈长度测量限制,与FDA近期说明书修改一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the use of the Ovation stent-graft according to the ≥7-mm neck length specified by the original instructions for use (IFU) vs those treated off-label (OL) for necks <7 mm long. METHODS: A multicenter retrospective registry (TriVascular Ovation Italian Study) database of all patients who underwent endovascular aneurysm repair with the Ovation endograft at 13 centers in Italy was interrogated to identify patients with a minimum computed tomography (CT) follow-up of 24 months, retrieving records on 89 patients (mean age 76.4±2.4 years; 84 men) with a mean follow-up of 32 months (range 24-50). Standard CT scans (preoperative, 1-month postoperative, and latest follow-up) were reviewed by an independent core laboratory for morphological changes. For analysis, patients were stratified into 2 groups based on proximal neck length ≥7 mm (IFU group, n=57) or <7 mm (OL group, n=32). Outcome measures included freedom from type Ia endoleak, any device-related reintervention, migration, and neck enlargement (>2 mm). RESULTS: At 3 years, there was no aneurysm-related death, rupture, stent-graft migration, or neck enlargement. There were no differences in terms of freedom from type Ia endoleak (98.2% IFU vs 96.8% OL, p=0.6; hazard ratio [HR] 0.55, 95% CI 0.02 to 9.71 or freedom from any device-related reintervention (92.8% IFU vs 96.4% OL, p=0.4; HR 2.42, 95% CI 0.34 to 12.99). In the sealing zone, the mean change in diameters was -0.05±0.8 mm in the IFU group and -0.1±0.5 mm in the OL group. CONCLUSION: Use of the Ovation stent-graft in patients with neck length <7 mm achieved midterm outcomes similar to patients with ≥7-mm-long necks. These midterm data show that the use of the Ovation system for the treatment of infrarenal abdominal aortic aneurysm is not restricted by the conventional measurement of aortic neck length, affirming the recent Food and Drug Administration-approved changes to the IFU.
引用
- de Donato G, Setacci F, Bresadola L, et al. Midterm Results of Proximal Aneurysm Sealing With the Ovation Stent-Graft According to On- vs Off-Label Use. J Endovasc Ther. 2017. PMID: 28058986. doi:10.1177/1526602816685581
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。